-
July 3, 2024
Toripalimab becomes Apotex's first novel brand biologic medicine.
-
June 3, 2024
Acquisition marks a significant step in Apotex's growth strategy, advancing its position as a preferred Health Partner of Choice in the Americas.
-
April 2, 2024
Canada's largest pharmaceutical company, Apotex Inc. ("Apotex") and Searchlight Pharma Inc. ("Searchlight"), one of Canada's fastest growing companies, announced today that they have reached an agreement whereby Apotex will acquire Searchlight.
-
February 16, 2024
Harrow, Inc., a leading U.S. eyecare pharmaceutical company, and Apotex Inc., Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.
-
April 19, 2023
-
April 3, 2023
-
September 28, 2022
Investment from SK Capital to support Apotex’s next phase of growth and continued innovation for patient affordability
-
July 20, 2022
Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-Apixaban™ tablets, Canada's first generic alternative to Eliquis®
-
May 17, 2022
Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the Canadian launch of APO-Teriflunomide™ tablets, a generic version of Aubagio®, for the treatment of relapsing remitting multiple sclerosis (RRMS).
-
April 12, 2022
Apotex Corp. announced today its release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane® in the United States.
-
February 2, 2021
-
May 26, 2020
-
May 26, 2020
-
May 25, 2020
-
April 21, 2020
-
April 17, 2020
-
April 13, 2020
-
March 23, 2020
-
March 5, 2020
-
September 20, 2018
Melbourne, September 20, 2018 – The Australian Competition and Consumer Commission (ACCC) announced this morning that it ‘has decided not to oppose the merger of generic pharmaceutical companies, Arrow and Apotex’ after finding the transaction would not substantially lessen competition in any market.